260 related articles for article (PubMed ID: 19891680)
21. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
Schiller B; Bhat P; Sharma A
Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
[TBL] [Abstract][Full Text] [Related]
22. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
23. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
[TBL] [Abstract][Full Text] [Related]
24. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
[TBL] [Abstract][Full Text] [Related]
25. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
26. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
27. Iron replacement and supplementation in patients with chronic kidney disease.
Wazny LD; Raymond CB
CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
[TBL] [Abstract][Full Text] [Related]
28. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
29. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.
Macdougall IC; Ashenden M
Adv Chronic Kidney Dis; 2009 Mar; 16(2):117-30. PubMed ID: 19233071
[TBL] [Abstract][Full Text] [Related]
30. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
31. Use of parenteral iron products and serious anaphylactic-type reactions.
Wysowski DK; Swartz L; Borders-Hemphill BV; Goulding MR; Dormitzer C
Am J Hematol; 2010 Sep; 85(9):650-4. PubMed ID: 20661919
[TBL] [Abstract][Full Text] [Related]
32. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
[TBL] [Abstract][Full Text] [Related]
33. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
34. Iron hydroxide polymaltose: iatrogenic cause of persistent iron deficiency anaemia despite continuous oral iron therapy.
Mehta BC
J Assoc Physicians India; 2002 Feb; 50():279-80. PubMed ID: 12038667
[No Abstract] [Full Text] [Related]
35. Intravenous iron products.
Johnson CA; Mason NA; Bailie GR
ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
[TBL] [Abstract][Full Text] [Related]
36. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.
Schröder O; Schrott M; Blumenstein I; Jahnel J; Dignass AU; Stein J
Z Gastroenterol; 2004 Aug; 42(8):663-7. PubMed ID: 15314711
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
38. Clinical perspective: iron replacement therapy in chronic heart failure.
Cowie MR; Lucas R
Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435
[No Abstract] [Full Text] [Related]
39. Iron (III) isomaltoside 1000.
Mace TA; Syed A; Bhandari S
Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
[TBL] [Abstract][Full Text] [Related]
40. An evidence-based approach to anaemia management in predialysis chronic kidney disease.
Pugh-Clarke K; Cooper L; Turner J; Fermin J
J Ren Care; 2009 Dec; 35 Suppl 2():29-31. PubMed ID: 19891683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]